HRP Conjugated Anti-His Tag Mouse Monoclonal Antibody (5C3) by Abbkine (Catalog ABT2055): Precision Engineered for His-Tagged Protein Detection

In the realm of recombinant protein research, His tags stand as one of the most widely adopted tools for protein purification, quantification, and localization—their small size, high affinity for metal ions, and minimal impact on protein structure make them indispensable across biotech, pharmaceuticals, and academic labs. Yet, the success of any His-tagged experiment hinges on the reliability of the detection antibody, and this is where Abbkine’s HRP Conjugated Anti-His Tag Mouse Monoclonal Antibody (clone 5C3), catalog number ABT2055 (available at https://www.abbkine.com/?s_type=productsearch&s=ABT2055), emerges as a standout solution. Meticulously designed to address the core demands of Western Blot (WB) assays, this antibody combines the specificity of monoclonal technology with the signal amplification power of Horseradish Peroxidase (HRP), delivering consistent, sensitive results across mammalian and bacterial systems. As the industry shifts toward reagents that prioritize reproducibility and efficiency, ABT2055 redefines what researchers can expect from a His tag detection tool—let’s explore its technical advantages, real-world applications, and the industry insights that position it as a must-have reagent.

Monoclonal specificity is the cornerstone of ABT2055’s performance, and the 5C3 clone is engineered to bind exclusively to His tags with unparalleled precision. Unlike polyclonal antibodies that recognize multiple epitopes (and risk cross-reactivity with endogenous proteins), monoclonal antibodies target a single, well-defined epitope on the His tag—ensuring that signals detected in WB assays originate solely from the His-tagged protein of interest. Abbkine’s rigorous clone selection process for 5C3 involves screening hundreds of hybridomas to identify the variant with the highest affinity and lowest off-target binding, followed by validation against non-His-tagged proteins in both mammalian (e.g., HEK293, CHO) and bacterial (e.g., E. coli) lysates. This level of specificity eliminates the background noise that plagues less refined antibodies, a critical advantage when working with low-abundance recombinant proteins or complex sample matrices. For researchers, this translates to cleaner blots, more accurate quantification, and reduced time spent troubleshooting—directly addressing the industry’s growing focus on data integrity and experimental reproducibility.

The integration of HRP conjugation into ABT2055’s design is a strategic choice that amplifies its utility in WB workflows. HRP remains the gold standard enzyme for immunoassays due to its high catalytic activity, stability, and compatibility with a wide range of chemiluminescent substrates—properties that enable sensitive detection of even picogram-levels of His-tagged proteins. Abbkine’s proprietary conjugation process ensures that the HRP enzyme is linked to the 5C3 antibody without compromising either the antibody’s binding affinity or the enzyme’s catalytic efficiency. This balance is crucial: poorly conjugated antibodies may exhibit weak signals (due to inactive HRP) or reduced specificity (due to altered antibody structure), but ABT2055 consistently delivers robust, dose-dependent signals across serial dilutions of His-tagged protein samples. For labs running high-throughput WB assays or working with limited sample volumes (e.g., purified recombinant proteins with low yields), this combination of sensitivity and reliability eliminates the need for secondary antibody incubation steps—streamlining workflows and reducing the risk of experimental variability.

Dual reactivity to mammals and bacteria positions ABT2055 as a versatile solution for researchers working across diverse expression systems. Recombinant proteins are frequently expressed in bacterial systems (for high-yield purification) before being validated in mammalian cells (to study function or localization), and most antibodies require separate reagents for each system—adding cost and complexity to workflows. Abbkine’s ABT2055 is validated to perform equally well in both, recognizing His-tagged proteins in E. coli lysates (including inclusion bodies and soluble fractions) and mammalian cell extracts (whether from adherent or suspension cultures). This cross-system compatibility aligns with the industry’s trend toward flexible, multi-purpose reagents that adapt to diverse research needs—eliminating the need to stock multiple antibodies and ensuring consistent performance when scaling experiments from bench to pilot. For example, a researcher studying a recombinant enzyme can use ABT2055 to confirm expression in E. coli via WB, then use the same antibody to validate its presence in mammalian cells—reducing protocol optimization time and ensuring data consistency across stages of the project.

While cost is a perpetual consideration in lab reagent selection, ABT2055 delivers exceptional value by balancing performance with a competitive price point of $109 for 50μl. When evaluating antibody value, it’s critical to consider not just upfront cost but also long-term efficiency: cheaper antibodies may require higher working concentrations (increasing reagent consumption) or result in failed experiments (wasting time and samples), while ABT2055’s high affinity allows for working dilutions of 1:1000–1:5000 in WB—extending the lifespan of each vial to dozens of assays. Additionally, its specificity and sensitivity reduce the need for expensive control reagents or repeat experiments, further lowering overall research costs. For biotech companies and academic labs alike, this value proposition aligns with the industry’s shift toward cost-effective, high-performance tools—especially as research budgets face increasing scrutiny. ABT2055 proves that researchers don’t have to sacrifice quality for affordability, a key differentiator in a market saturated with low-quality, budget-friendly alternatives.

From an industry perspective, ABT2055 reflects two critical trends shaping the antibody market: the demand for application-specific reagents and the emphasis on clone-specific validation. Western Blot remains the most common technique for protein detection, but many antibodies are marketed as “multi-application” without rigorous validation for each use case—leading to inconsistent results. Abbkine’s focus on optimizing ABT2055 specifically for WB ensures that every aspect of its design (from epitope recognition to conjugation efficiency) is tailored to the unique demands of this assay. Additionally, the inclusion of the 5C3 clone designation provides transparency—a growing priority for researchers and journals, which increasingly require detailed reagent information to ensure experiment reproducibility. By specifying the clone, Abbkine enables researchers to replicate results across labs and batches, addressing a longstanding pain point in the life sciences where antibody variability has hindered scientific progress. As the industry moves toward more standardized, transparent reagent development, ABT2055 sets a benchmark for clone-specific, application-optimized antibodies.

Practical considerations for maximizing ABT2055’s performance further enhance its utility for researchers. For optimal WB results, Abbkine recommends blocking membranes with 5% non-fat milk in TBST for 1 hour at room temperature—this balances background reduction with preservation of antibody binding. The antibody should be diluted in blocking buffer at 1:2000 (a starting point; adjust based on signal intensity) and incubated with membranes overnight at 4°C to maximize binding specificity. When paired with a high-quality chemiluminescent substrate, ABT2055 detects His-tagged proteins as low as 1 ng, making it suitable for both qualitative (expression confirmation) and quantitative (relative protein abundance) analyses. Storage is equally straightforward: aliquoting the antibody and storing at -20°C prevents repeated freeze-thaw cycles, which can degrade HRP activity, ensuring consistent performance for up to 12 months. These practical guidelines, paired with the antibody’s inherent technical strengths, make ABT2055 accessible to researchers of all experience levels—from graduate students to senior scientists.

In conclusion, Abbkine’s HRP Conjugated Anti-His Tag Mouse Monoclonal Antibody (5C3) (catalog ABT2055) is more than a detection reagent—it’s a precision tool engineered to address the core challenges of His-tagged protein research. Its monoclonal specificity eliminates background noise, HRP conjugation delivers sensitive signal amplification, dual reactivity spans key expression systems, and its value proposition balances quality with affordability. As the life sciences industry continues to prioritize reproducibility, efficiency, and transparency, ABT2055 aligns perfectly with these goals—empowering researchers to generate reliable, publishable data while streamlining workflows. Whether you’re validating recombinant protein expression in bacteria, quantifying His-tagged proteins in mammalian cells, or running high-throughput WB assays, this antibody delivers the consistency and performance that modern research demands. To integrate ABT2055 into your lab toolkit, visit its product page at https://www.abbkine.com/?s_type=productsearch&s=ABT2055—and elevate your His-tagged protein detection to the next level.

For researchers seeking a reliable, specific, and versatile solution for His tag detection, ABT2055 stands out as a leader in its class. Its technical advantages, industry-aligned design, and practical utility make it a valuable asset for any lab working with recombinant proteins—proving that when it comes to antibody selection, precision and purpose drive success.